Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C

Chew KW, Allen SA, Taylor LE, Rich JD, Feller E. Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C. J Clin Gastroenterol. 2009;43(7):686-691.

Publication Type:

Journal Article

Authors:

Chew, K.W.; Allen, S.A.; Taylor, L.E.; Rich, J.D.; Feller, E.

Source:

J Clin Gastroenterol, Volume 43, Issue 7, p.686-691 (2009)

Keywords:

Adult, adverse effects, African Americans, Antibodies, Antiviral Agents, Biopsy, California, chronic HCV, Disease, drug therapy, Drug Therapy,Combination, ethnology, European Continental Ancestry Group, Follow-Up Studies, genetics, Genotype, genotype 1, Goals, Guidelines, HCV, Hepacivirus, hepatitis, Hepatitis C, hepatitis C virus, Hepatitis C,Chronic, Humans, interferon, Interferon Alfa-2b, Interferon-alpha, Liver, Lost to Follow-Up, Male, Medicine, Middle Aged, Patients, peginterferon, peginterferon alfa-2b, pegylated, pegylated interferon, Polyethylene Glycols, Prisoners, Prisons, Proteins, Recombinant Proteins, Research, Research Support, Retrospective Studies, Rhode Island, Ribavirin, Risk, Risk Factors, San Francisco, sustained virologic response, SVR, therapeutic use, therapy, Time, treatment, Treatment Outcome, Young Adult

Notes:

PMC2936234

Cited On:

When and in Whom to Initiate HCV Therapy

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/19295448

Export Citation:

RIS Format

Top